Hepamerz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

# Hepamerz (l-Ornithine l-Aspartate) ## Overview Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. ## Primary Indications Treatment of latent and manifest hepatic encephalopathy (HE). ## Adult Dosing * **Latent HE:** 3 sachets (9 g l-ornithine l-aspartate) orally three times daily for 7 days, followed by 2 sachets (6 g l-ornithine l-aspartate) orally twice daily for up to 14 days. * **Manifest HE:** Typically initiated with intravenous administration, followed by oral therapy. Oral doses of 3 sachets (9 g l-ornithine l-aspartate) three times daily are often used, but specific oral dosing following IV initiation is not definitively established and may vary. ## Pediatric Dosing Data on pediatric use is limited. Dosing is not established and should be determined by a specialist. ## Dose Adjustments No specific dose adjustments are routinely recommended for renal or hepatic impairment, but caution is advised, especially in patients with severe liver disease. ## Contraindications * Hypersensitivity to l-ornithine l-aspartate or any excipients. * Severe kidney disease (creatinine clearance < 25 mL/min) due to potential accumulation. * Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency if the product contains sucrose. ## Adverse Effects Generally well-tolerated. Gastrointestinal disturbances (nausea, vomiting, abdominal pain, diarrhea) may occur. ## Key Drug Interactions None well-established. ## Monitoring * Monitor for signs and symptoms of hepatic encephalopathy. * Monitor kidney function, especially in patients with pre-existing renal impairment or at risk. ## Clinical Pearls * l-Ornithine promotes the conversion of ammonia to urea in the liver and the detoxification of ammonia in peripheral tissues. * l-Aspartate is involved in the urea cycle and energy metabolism. * Oral administration is typically used for latent HE and as maintenance therapy after IV treatment for manifest HE. *** **Disclaimer:** This information is intended for healthcare professionals. Always verify the most current prescribing information with official drug product labeling and relevant clinical guidelines before making any treatment decisions.